Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 09/26 04:59:36 pm
296.2 DKK   -0.20%
09/26 NOVO NORDISK A/ : submits application in the US for including data f..
09/26 NOVO NORDISK A/ : - Share repurchase programme
09/23 NOVO NORDISK A/ : submits application in the US for including data f..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/13/2012 | 10:15am CEST
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVO NORDISK A/S
09/26 NOVO NORDISK A/S : submits application in the US for including data from the two..
09/26 NOVO NORDISK A/S : - Share repurchase programme
09/23 NOVO NORDISK A/S : submits application in the US for including data from the two..
09/21 NOVO NORDISK A/S : semaglutide reduced major cardiovascular events in 1 in 4 typ..
09/20 NOVO NORDISK A/S : Diabetes Campaign Launched in Nigeria to Promote Early Diagno..
09/19 NOVO NORDISK A/S : NovoRapid receives positive CHMP opinion for extended use in ..
09/19 NOVO NORDISK A/S : - Share repurchase programme
09/16 NOVO NORDISK A/S : Victoza lowered the progression of kidney damage in adults wi..
09/16 NOVO NORDISK A/S : NovoRapid® receives positive CHMP opinion for extended use in..
09/15 NOVO NORDISK A/S : Inc. issues voluntary nationwide recall of six batches of Glu..
More news
Sector news : Pharmaceuticals - NEC
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/23 Novo submits application to FDA to include beefed up data in Tresiba label
09/19 Healthcare Top Dogs See Big Pharma Up 6-4 In September Gains
09/19 NASTY WEEKEND : Time To Think Through Trump-Era Investing
09/13 Google's Diabetes Partnerships Could Be Just The Start
09/13 Astra And Lexicon Provide The Good News In Diabetes
Advertisement
Financials ( DKK)
Sales 2016 113 146 M
EBIT 2016 49 205 M
Net income 2016 38 289 M
Finance 2016 11 894 M
Yield 2016 2,44%
P/E ratio 2016 19,58
P/E ratio 2017 17,93
EV / Sales 2016 5,17x
EV / Sales 2017 4,88x
Capitalization 597 329 M
More Financials
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 363  DKK
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Rebien Sørensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Alan C. Moses Global Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-25.78%90 059
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results